plasmapheresis

PreclinicalSmall molecule

MMayo Clinic

plasmapheresis is one of 34 small molecule programs targeting Encephalopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EncephalopathyActive, not recruiting

COVIDWithdrawn

EncephalopathyPreclinical

Active, not recruiting

COVIDPreclinical

Withdrawn

Competition

Competitive Landscape

41 competitors in Encephalopathy

#DrugCompanyPhaseTrials

Chronulac

SSolvay Pharmaceuticals

Approved

27 2

Golytely

Bayer

Approved

1 3

Zyloprim

Glucophage

1 5

Osmitrol

BB. Braun Medical Inc.

Approved

—6

Carnitor

LLeadiant Biosciences, Inc.

Approved

—7

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Approved

2 8

Alinia

RRomark Laboratories L.C.

Phase 3

4 9

PROCRIT

WWim Janssens

Phase 3

3 10

Citicoline

UUniversity of Texas Southwestern Medical Center

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Disease Progression1 trial

Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

Completed·MMayo Clinic·Phase 1·NCT03887741·3 enrolled

COVID1 trial

Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID

Withdrawn·HHôpital Européen Marseille·N/A·NCT05543590

MPA1 trial

Belimumab Impacting Transplant Eligibility

Completed·EE. Steve Woodle·Phase 1/2·NCT02500251·11 enrolled

Kidney Transplant1 trial

Desensitization in Kidney Transplantation

Completed·UUniversity of Cincinnati·Phase 4·NCT00908583·44 enrolled

Encephalopathy1 trial

High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.

Withdrawn·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03115697

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for plasmapheresis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — plasmapheresis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for plasmapheresis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMayo Clinic

plasmapheresis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Disease Progression1 trial

COVID1 trial

MPA1 trial

Kidney Transplant1 trial

Encephalopathy1 trial

References

Drug Info

Quick Facts

Related News